Beta thalassemia

Beta-thalassemia
Other namesCooley's anemia, Mediterranean anemia[1]
Beta-thalassemia genetics, the picture shows one example of how beta-thalassemia is inherited. The beta-globin gene is located on chromosome 11. A child inherits two beta globin genes (one from each parent).
SpecialtyHematology
SymptomsAnemia, enlarged spleen, abnormal bone structure[1]
Usual onsetBetween 6 and 24 months of age[1]
TypesBeta-thalassemia minor, intermedia and major[2]
CausesMutations in the HBB gene[3]
Risk factorsFamily history, ancestry from the Mediterranean, West Africa, the Middle East, the Indian subcontinent or Southeast Asia[4][5]
Diagnostic methodBlood smear, hemoglobin electrophoresis, iron & ferritin tests, DNA analysis[6]
Differential diagnosisAlpha thalassemia, sickle cell disease, iron deficiency anemia
PreventionPreconception genetic counseling
TreatmentBlood transfusion, iron chelation, stem cell transplant, gene therapy

Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severe anemia individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood.[7] Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues.[8]

Beta thalassemia occurs due to a mutation of the HBB gene leading to deficient production of the hemoglobin subunit beta-globin; the severity of the disease depends on the nature of the mutation, and whether or not the mutation is homozygous.[9][10] The body's inability to construct beta-globin leads to reduced or zero production of adult hemoglobin thus causing anemia.[11] The other component of hemoglobin, alpha-globin, accumulates in excess leading to ineffective production of red blood cells, increased hemolysis, and iron overload.[12] Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing.[13]

As an inherited condition, beta thalassemia cannot be prevented although genetic counselling of potential parents prior to conception can propose the use of donor sperm or eggs.[14] Patients may require repeated blood transfusions throughout life to maintain sufficient hemoglobin levels; this in turn may lead to severe problems associated with iron overload.[1] Medication includes folate supplementation, iron chelation, bisphosphonates, and removal of the spleen.[15] Beta thalassemia can also be treated by bone marrow transplant from a well matched donor,[16] or by gene therapy.[17]

Thalassemias were first identified in severely sick children in 1925,[18] with identification of alpha and beta subtypes in 1965.[19] Beta-thalassemia tends to be most common in populations originating from the Mediterranean, the Middle East, Central and Southeast Asia, the Indian subcontinent, and parts of Africa. This coincides with the historic distribution of Plasmodium falciparum malaria, and it is likely that a hereditary carrier of a gene for beta-thalassemia has some protection from severe malaria. However, because of population migration, β-thalassemia can be found around the world.[13] In 2005, it was estimated that 1.5% of the world's population are carriers and 60,000 affected infants are born with the thalassemia major annually.[20]

  1. ^ a b c d Galanello R, Origa R (May 2010). "Beta-thalassemia". Orphanet Journal of Rare Diseases. 5: 11. doi:10.1186/1750-1172-5-11. PMC 2893117. PMID 20492708.
  2. ^ Advani P. "Beta Thalassemia Treatment & Management". Medscape. Archived from the original on 4 April 2017. Retrieved 4 April 2017.
  3. ^ Cite error: The named reference genh was invoked but never defined (see the help page).
  4. ^ Fattoum S (10 November 2009). "Evolution of hemoglobinopathy prevention in Africa: results, problems and prospect". Mediterranean Journal of Hematology and Infectious Diseases. pp. e2009005. doi:10.4084/MJHID.2009.005.
  5. ^ Kattamis A, Forni GL, Aydinok Y, Viprakasit V (December 2020). "Changing patterns in the epidemiology of β-thalassemia". European Journal of Haematology. pp. 692–703. doi:10.1111/ejh.13512.
  6. ^ McKinney ES, James SR, Murray SS, Nelson K, Ashwill J (2014-04-17). Maternal-Child Nursing. Elsevier Health Sciences. ISBN 978-0-323-29377-8. Archived from the original on 2023-01-14. Retrieved 2020-10-25.
  7. ^ Lanzkowsky's Manual Of Pediatric Hematology And Oncology 6th Edition ( 2016).
  8. ^ "Beta Thalassemia". Johns Hopkins Medicine. Archived from the original on 2025-01-25. Retrieved 2025-02-18.
  9. ^ Goldman L, Schafer AI (2015-04-21). Goldman-Cecil Medicine: Expert Consult — Online. Elsevier Health Sciences. ISBN 978-0-323-32285-0.
  10. ^ Bajwa H, Basit H (2025). "Thalassemia". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31424735. Retrieved 2025-02-18.
  11. ^ Carton J (2012-02-16). Oxford Handbook of Clinical Pathology. OUP Oxford. ISBN 978-0-19-162993-8. Archived from the original on 2023-01-14. Retrieved 2020-10-25.
  12. ^ Kattamis A, Kwiatkowski JL, Aydinok Y (June 2022). "Thalassaemia". Lancet. 399 (10343): 2310–2324. doi:10.1016/S0140-6736(22)00536-0. PMID 35691301.
  13. ^ a b Langer AL (8 February 2024). "Beta-Thalassemia". In Adam MP, Feldman J, Mirzaa GM (eds.). GeneReviews®. University of Washington, Seattle. PMID 20301599. Retrieved 2025-02-18.
  14. ^ "Thalassaemia - Thalassaemia carriers". National Health Service. 17 October 2022. Retrieved 2025-01-27.
  15. ^ "Alpha Thalassemia". Johns Hopkins Medicine. 27 January 2025. Retrieved 27 January 2025.
  16. ^ "Clinical commissioning policy: allogeneic haematopoietic stem cell transplantation (Allo-HSCT) for adult transfusion dependent thalassaemia". NHS England. 2023-11-10. Retrieved 2025-01-18.
  17. ^ "MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 16 November 2023. Archived from the original on 25 November 2023. Retrieved 8 December 2023.
  18. ^ Stuart H. Orkin, David G. Nathan, David Ginsburg, A. Thomas Look (2009). Nathan and Oski's Hematology of Infancy and Childhood, Volume 1. Elsevier Health Sciences. pp. 1054–1055. ISBN 978-1-4160-3430-8.
  19. ^ Harteveld CL, Higgs DR (May 2010). "Alpha-thalassaemia". Orphanet Journal of Rare Diseases. 5 (1): 13. doi:10.1186/1750-1172-5-13. PMC 2887799. PMID 20507641.
  20. ^ Cite error: The named reference Rao-2024 was invoked but never defined (see the help page).